4.强化产研协同与数据资产积累：与北京健国医疗的合作，进一步巩固了公司与国家级科研机构的协作 网络。共建长期研究队列所获得的真实世界数据，将成为驱动公司算法迭代、产品优化及创新研发的宝 贵资产。 2.推动行业标准建立与市场规范化：参与国标研究与多中心样本验证，不仅有助于积累高级别循证医学 证据，更能直接参与行业标准的塑造。这将提升公司解决方案的行业认可度与权威性，为产品在全国范 围内的大规模推广奠定坚实基础。 3.拓展普惠性服务网络与社会影响力：项目聚焦于精神卫生福利机构及社区场景，旨在提升基层与特定 机构的认知障碍服务能力。成功实施将显着扩大公司产品与服务的覆盖人群，特别是提升在公共卫生与 社会福利体系中的渗透率，创造显着社会效益的同时，开拓新的市场增长空间。 脑动极光-B(06681)发布公告，公司的间接全资附属公司浙江脑动极光医疗科技有限公司("浙江脑动极 光")已与北京健国医疗科技有限公司("北京健国医疗")正式签署《认知数字疗法项目合作协议》。双方 将于2026年1月1日至2026年12月30日期间，围绕"认知功能评估训练精神卫生应用场景构建与推广应 用"课题开展深度合作，共同推动认知障碍数字疗法的 ...

智通财经APP讯，脑动极光-B(06681)发布公告，公司的间接全资附属公司浙江脑动极光医疗科技有限公 司("浙江脑动极光")已与北京健国医疗科技有限公司("北京健国医疗")正式签署《认知数字疗法项目合 作协议》。双方将于2026年1月1日至2026年12月30日期间，围绕"认知功能评估训练精神卫生应用场景 构建与推广应用"课题开展深度合作，共同推动认知障碍数字疗法的标准化、规模化与可及化。 本次合作是公司继参与国家科技重大专项及获批认知障碍数字疗法北京市重点实验室后，在认知障碍数 字疗法应用落地与生态构建方面的又一重要举措。具体而言，本次合作将： 1.深化精神健康领域技术探索与产品化：通过与国家级研究中心的课题执行方合作，公司将深入精神卫 生这一特定应用场景，探索并验证数字疗法在评估、训练及管理路径上的创新模式。这有助于将前沿人 工智能算法与临床实际需求深度融合，催生更精准、更普适的技术产品，拓展数字疗法在精神健康领域 的应用边界。 4.强化产研协同与数据资产积累：与北京健国医疗的合作，进一步巩固了公司与国家级科研机构的协作 网络。共建长期研究队列所获得的真实世界数据，将成为驱动公司算法迭代、产品优化及创新 ...

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance Metrics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [2][3]. - The highest price reached was 13.78 HKD, while the lowest was 5.22 HKD, with a total volume of 3.812 billion shares traded during this period [3]. Group 2: Market Dynamics - The significant turnover rate of 30.107% indicates a major shift in the shareholder structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [3]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support level for future price movements [3]. Group 3: Trading Behavior Analysis - The K-line patterns revealed a complex interplay between bulls and bears, with four days of price increases but only three days showing positive closing prices, indicating a fierce battle between buying and selling pressures [4][6]. - Despite the apparent selling pressure, the volume of buying (3.572 billion shares) was significantly higher than selling (0.24 billion shares), demonstrating strong underlying demand [7]. Group 4: Investor Composition - Data shows that southbound funds were the primary drivers of this rally, with nearly 944.3 million shares acquired through the Hong Kong Stock Connect within just five days, representing 0.7458% of the total issued shares [8][10]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [10]. Group 5: Future Outlook - As of September 15, the stock was trading at 10.22 HKD, reflecting a 36.27% increase for the day, with a trading volume of 21.43 billion HKD, suggesting a transition into a new phase of market activity [11]. - The market is currently in a high-level consolidation phase after a rapid price increase, with future price stability dependent on continued inflows from southbound funds and the company's ability to validate its growth potential [11].

Core Viewpoint - The stock of Brainstorm Cell Therapeutics (06681) experienced a dramatic surge, rising over 83% to reach a new high of 13.78 HKD, driven by its inclusion in the Hong Kong Stock Connect and the scarcity of its position as the first domestic company focused on digital therapies for cognitive disorders [1][2]. Group 1: Stock Performance and Market Dynamics - From September 8 to September 15, the stock exhibited an impressive increase of 88.91%, with a volatility of 158.23% and a turnover rate of 30.107%, resulting in a total trading volume of 35.4 billion HKD [1][2]. - The turnover rate of 30.107% indicates a significant shift in shareholding structure, with nearly one-third of the floating shares changing hands, suggesting a complete overhaul of the previous holding patterns [2]. - The average holding cost for the market has risen to 9.286 HKD, establishing a solid support line for future price movements [2]. Group 2: Market Sentiment and Trading Behavior - The K-line pattern during this period showed a paradox where the stock rose for four days but only recorded three bullish candles, indicating a fierce battle between bulls and bears [3][5]. - Despite the apparent selling pressure, the volume of buying was significantly higher, with bullish volume at 3.572 billion shares, which is 14.88 times the bearish volume, indicating strong buying interest [6]. Group 3: Investor Composition and Market Drivers - Southbound funds were identified as the primary drivers of this rally, with nearly 944.3 million shares acquired through the Stock Connect channels within just five days, representing 0.7458% of the total issued shares [7][9]. - In contrast, local brokers like Yao Cai Securities and Bank of China (Hong Kong) showed much smaller increases in holdings, indicating that their activities were more of a follow-up to the main buying momentum [9]. Group 4: Future Outlook - The stock is currently in a high volatility phase following a significant price increase, with ongoing battles between buyers and sellers in the 10.00-11.00 HKD range [10]. - The future price stability will depend on two key factors: the continued inflow of southbound funds and the company's ability to validate its high growth potential to match the new valuation [10].